📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
58 announcements match the current filters (relevance ≥ 5).
Fortis Healthcare Seeks Approval for ESOP 2026 Scheme Involving 1.51 Crore Options
Fortis Healthcare has initiated a postal ballot to seek shareholder approval for the 'Fortis Healthcare Limited Employee Stock Option Scheme 2026'. The proposal involves granting up to 1,50,99,163 stock options to eligible employees of the company, its subsidiaries, and associate companies. Each option will be convertible into one equity share of face value Rs. 10 upon exercise. The e-voting period for shareholders is scheduled from February 17, 2026, to March 18, 2026.
Key Highlights
Proposed issuance of up to 1,50,99,163 employee stock options under the new ESOP 2026 scheme.
Each option is exercisable into one equity share of face value Rs. 10/- fully paid-up.
Scheme extends to eligible employees of the company, its subsidiaries, and associate companies globally.
Excludes promoters, independent directors, and directors holding more than 10% of outstanding equity shares.
Voting period for the special resolution runs from February 17 to March 18, 2026.
👀 What to Watch
Investors should note that while ESOPs lead to minor equity dilution, they are standard tools for talent retention in the healthcare sector. No immediate action is required beyond participating in the postal ballot if they wish to vote on the compensation structure.
Fortis Healthcare to Launch ESOP 2026 Scheme for 1.51 Crore Equity Shares
Fortis Healthcare is seeking shareholder approval via postal ballot for the implementation of the 'Fortis Healthcare Limited Employee Stock Option Scheme 2026'. The proposal involves granting up to 1,50,99,163 options to eligible employees of the company, its subsidiaries, and associate companies. Each option will be convertible into one equity share of face value Rs. 10 upon exercise. The e-voting period for shareholders is scheduled from February 17, 2026, to March 18, 2026.
Key Highlights
Proposed ESOP 2026 scheme covers a maximum of 1,50,99,163 equity shares.
One stock option converts into one equity share of Rs. 10 face value.
Scheme includes eligible employees of the parent company, subsidiaries, and associate firms.
The voting period for the special resolution ends at 5:00 p.m. IST on March 18, 2026.
👀 What to Watch
Investors should evaluate the potential equity dilution from the 1.51 crore shares against the benefits of talent retention. No immediate action is required other than participating in the postal ballot voting.
Fortis Q3 Standalone Revenue Rises 20.7% YoY to ₹443 Cr; New ESOP Scheme Approved
Fortis Healthcare reported a 20.7% YoY growth in standalone revenue from operations to ₹442.93 crore for the quarter ended December 31, 2025. However, standalone net profit declined by 28.2% YoY to ₹28.40 crore, primarily due to a significant spike in finance costs and professional fees. The board has also approved a new Employee Stock Option Scheme (ESOP 2026) covering 1.51 crore shares to incentivize talent. Investors should note that legal overhangs regarding past promoter transactions and SFIO investigations remain ongoing.
Key Highlights
Standalone Revenue from operations increased to ₹44,293 lacs from ₹36,687 lacs in the previous year's quarter.
Standalone Net Profit for Q3 FY26 stood at ₹2,840 lacs compared to ₹3,956 lacs in Q3 FY25.
Finance costs more than doubled YoY, rising from ₹2,651 lacs to ₹5,566 lacs in the current quarter.
Board approved ESOP 2026 scheme with a pool of 1,50,99,163 options, each convertible into one equity share.
Ongoing SFIO investigations and Supreme Court-directed forensic audits regarding RHT Health Trust transactions continue to be monitored.
👀 What to Watch
While top-line growth is healthy, investors should monitor the rising finance costs and the impact of the new ESOP scheme on equity dilution. The long-term legal risks associated with past promoter actions remain a critical factor for the stock's valuation.
Fortis Q3 FY26: Revenue up 17.5% to ₹2,265 Cr, Operating EBITDA jumps 34.8%
Fortis Healthcare reported a strong operational performance for Q3 FY26, with consolidated revenues growing 17.5% YoY to ₹2,265 crore. Operating EBITDA saw a significant jump of 34.8% to ₹505 crore, driven by margin expansion in both hospital (21.7%) and diagnostic (23.1%) segments. While reported PAT was impacted by a one-time exceptional loss of ₹45.9 crore related to new labor codes, the core business remains robust with a 14% increase in occupied beds. The company also expanded its footprint by acquiring People Tree Hospital in Bengaluru for ₹430 crore in January 2026.
Key Highlights
Consolidated Operating EBITDA grew 34.8% YoY to ₹505 Cr with margins expanding to 22.3% from 19.4%.
Hospital business revenue rose 19.4% to ₹1,938 Cr, supported by a 14% increase in occupied beds and higher ARPOB of ₹2.56 Cr.
Diagnostics business (Agilus) saw a sharp margin recovery to 23.1% from 14.4% in the corresponding previous quarter.
Net debt increased to ₹2,547 Cr (1.24x EBITDA) following the Agilus stake acquisition and Shrimann Hospital investment.
Acquired 125-bedded People Tree Hospital in Bengaluru for ₹430 Cr with potential to scale to 300+ beds.
👀 What to Watch
Investors should focus on the strong operational EBITDA growth and significant margin expansion in the diagnostics segment. The inorganic expansion strategy in key clusters like Bengaluru and the recovery in Agilus provide a positive outlook for long-term value creation.
Fortis Q3 FY26: Revenue up 17.5% to ₹2,265 Cr; Operating EBITDA jumps 34.8%
Fortis Healthcare reported a strong operational performance for Q3 FY26, with consolidated revenues growing 17.5% YoY to INR 2,265 Cr. Operating EBITDA saw a significant jump of 34.8% to INR 505 Cr, driven by margin expansion in both hospital (21.7%) and diagnostic (23.1%) segments. While Profit After Tax fell 22.4% to INR 197 Cr due to a one-time exceptional loss related to new labor codes, Profit Before Tax (before exceptions) grew 21.9%. The company also strengthened its footprint through the INR 430 Cr acquisition of People Tree Hospital in Bengaluru.
Key Highlights
Consolidated Revenue grew 17.5% YoY to INR 2,265 Cr, with Hospital business contributing INR 1,938 Cr.
Operating EBITDA margins improved significantly to 22.3% from 19.4% in the previous year's quarter.
Diagnostics business (Agilus) showed a sharp recovery with EBITDA margins rising to 23.1% from 14.4%.
Net debt increased to INR 2,547 Cr (1.24x EBITDA) following acquisitions of Agilus PE stake and Shrimann Hospital.
Acquired 125-bedded People Tree Hospital in Bengaluru for INR 430 Cr to expand southern presence.
👀 What to Watch
Investors should focus on the robust 34.8% growth in operating EBITDA and margin expansion rather than the exceptional-item-led PAT decline. The aggressive inorganic expansion in Bengaluru and recovery in the diagnostics segment are positive long-term indicators.
Fortis Healthcare Q3 Standalone Revenue Up 20.7% to ₹443 Cr; Board Approves 1.51 Cr ESOP Pool
Fortis Healthcare reported a standalone revenue of ₹442.93 crore for Q3 FY26, a 20.7% increase from ₹366.87 crore in the same quarter last year. However, standalone net profit for the quarter declined to ₹28.40 crore from ₹39.56 crore YoY, primarily due to a sharp rise in finance costs which reached ₹55.66 crore. The board has also approved a new Employee Stock Option Scheme (ESOP 2026) with a pool of 1.51 crore shares to attract and retain talent. Investors should remain aware of the ongoing SFIO investigations and legal matters regarding erstwhile promoters mentioned in the auditor's report.
Key Highlights
Standalone revenue from operations grew 20.7% YoY to ₹442.93 crore in Q3 FY26.
Standalone net profit decreased to ₹28.40 crore in Q3 FY26 compared to ₹39.56 crore in Q3 FY25.
Finance costs surged to ₹55.66 crore in the current quarter from ₹26.51 crore in the previous year's corresponding quarter.
Board approved ESOP 2026 scheme involving 1,50,99,163 equity shares, subject to shareholder approval.
Auditors maintained an emphasis of matter regarding ongoing SFIO investigations and Supreme Court orders related to RHT Health Trust.
👀 What to Watch
Investors should monitor the consolidated financial performance to assess the impact of diagnostic and subsidiary segments. The increase in finance costs and the legal overhang from legacy promoter issues remain key monitorables.
Fortis Healthcare Q3 Standalone Revenue Up 20.7% YoY; Board Approves New ESOP Scheme
Fortis Healthcare reported a standalone revenue of ₹442.93 crore for Q3 FY26, marking a 20.7% growth over the same period last year. However, standalone net profit for the quarter saw a decline to ₹28.40 crore from ₹39.56 crore YoY, largely impacted by finance costs which more than doubled to ₹55.66 crore. For the nine-month period ended December 2025, the company's performance remains strong with a net profit of ₹205.37 crore compared to ₹106.02 crore in the previous year. Additionally, the board has approved a new ESOP scheme for 1.51 crore shares to align employee interests with shareholder value.
Key Highlights
Standalone Revenue from operations grew 20.7% YoY to ₹442.93 crore in Q3 FY26.
Net Profit for the quarter stood at ₹28.40 crore, down from ₹39.56 crore in the previous year's corresponding quarter.
Finance costs surged significantly to ₹55.66 crore in Q3 FY26 compared to ₹26.51 crore in Q3 FY25.
Board approved 'ESOP 2026' scheme covering 1,50,99,163 equity shares subject to shareholder approval.
Auditors highlighted ongoing legacy legal matters including SFIO investigations and Supreme Court observations on RHT Health Trust.
👀 What to Watch
Investors should monitor the impact of rising finance costs on the bottom line and keep a close watch on the resolution of legacy legal and regulatory investigations. While the nine-month growth trajectory is positive, the quarterly profit dip suggests a need for cautious observation of operational margins.
Fortis Shareholders Approve Appointment of Mohd Shahazwan Bin Mohd Harris with 99.39% Majority
Fortis Healthcare shareholders have approved the appointment of Mr. Mohd Shahazwan Bin Mohd Harris as a Non-Independent & Non-Executive Director via postal ballot. The resolution saw high participation, with 86.73% of outstanding shares being polled. The appointment was passed with an overwhelming 99.39% majority, reflecting strong confidence from both promoters and institutional investors.
Key Highlights
Appointment of Mr. Mohd Shahazwan Bin Mohd Harris as Non-Executive Director approved.
Resolution received 650,781,446 votes in favour (99.39%) and 3,975,127 votes against (0.61%).
Promoter group supported the resolution with 100% of their 235.3 million votes.
Public institutional support was high at 98.96% out of 379.7 million votes polled.
👀 What to Watch
This is a routine board appointment with high shareholder consensus; no immediate action is required.
Fortis Healthcare Receives NCLT Approval for Merger of Four Wholly-Owned Subsidiaries
Fortis Healthcare has received final NCLT approval to merge four of its wholly-owned subsidiaries—FESL, FCCL, FHMEL, and B&B—into Fortis Hospitals Limited (FHsL). The merger is effective from the appointed date of April 1, 2022, and is aimed at streamlining operations and reducing administrative overheads. As the entities involved are all wholly-owned subsidiaries, there will be no issuance of new shares or cash consideration, and the shareholding pattern of the listed parent remains unchanged. FHsL, the transferee company, reported a turnover of INR 12,824.21 million for the period ending March 31, 2025.
Key Highlights
NCLT Chandigarh and New Delhi have approved the merger of four subsidiaries into Fortis Hospitals Limited (FHsL).
The merger includes Fortis Emergency Services, Fortis Cancer Care, Fortis Health Management (East), and Birdie & Birdie Realtors.
The appointed date for the scheme is April 01, 2022, with FHsL reporting a turnover of INR 12,824.21 million in FY25.
No cash consideration or share issuance is involved as all entities are 100% owned within the group.
Rationale for the merger is to achieve cost rationalization and simplification of the management structure.
👀 What to Watch
This is an internal corporate restructuring that simplifies the group structure without impacting consolidated financials or shareholding. Investors should view this as a positive step toward operational efficiency and reduced compliance costs.
Fortis Healthcare Receives NCLT Approval for Merger of Five Wholly-Owned Subsidiaries
Fortis Healthcare has received final NCLT approval for the merger of four wholly-owned subsidiaries (FESL, FCCL, FHMEL, and B&B) into Fortis Hospitals Limited (FHsL). The consolidation is designed to enhance operational efficiencies and reduce administrative and managerial overheads. As the entities are wholly-owned, there will be no issuance of new shares or cash consideration, ensuring no dilution for existing shareholders. The primary transferee, FHsL, reported a turnover of INR 12,824.21 million as of March 31, 2025.
Key Highlights
NCLT New Delhi and Chandigarh approved the scheme on Jan 5 and Jan 16, 2026, respectively.
The merger involves four subsidiaries being absorbed into Fortis Hospitals Limited (FHsL).
FHsL's turnover stood at INR 12,824.21 million with a paid-up capital of INR 799.88 million as of FY25.
The appointed date for the scheme is April 01, 2022, and it involves no share exchange or cash payout.
Restructuring aims to simplify management structure and achieve cost rationalization in financial reporting.
👀 What to Watch
No immediate action is required as this is an internal consolidation with no impact on the listed entity's shareholding. Investors should monitor for long-term margin improvements resulting from reduced administrative costs.
Fortis Subsidiary Consummates Acquisition of TMI Healthcare Operations and Assets
Fortis Healthcare's wholly-owned subsidiary, International Hospital Limited (IHL), has successfully completed the acquisition of TMI Healthcare Private Limited. The transaction includes the hospital's operations along with the underlying land, building, and adjacent land parcels. This follows the definitive agreements previously entered into on December 20, 2025. The completion of this deal signifies Fortis's continued focus on expanding its physical infrastructure and service capacity.
Key Highlights
Wholly-owned subsidiary International Hospital Limited (IHL) finalized the acquisition on January 9, 2026.
Acquisition covers both hospital operations and the ownership of underlying land and buildings.
The transaction includes adjacent land, providing potential for future brownfield expansion.
Follows the initial disclosure of definitive agreements made on December 20, 2025.
👀 What to Watch
Investors should view this as a positive expansion move and watch for the impact on bed capacity and operational margins in the next earnings cycle.
Fortis Healthcare Plans 3,200+ Bed Expansion by FY30; H1FY26 EBITDA Margin Hits 23.3%
Fortis Healthcare has outlined an aggressive expansion strategy to add over 3,200 beds by FY30, aiming for a total capacity of 8,061 beds. The company reported strong financial performance with H1FY26 consolidated revenue at INR 44,982 Mn and a significantly improved operating EBITDA margin of 23.3%. Hospital ARPOB grew 4.2% YoY to INR 24.9 Mn in H1FY26, while the diagnostics business maintained a healthy 24.6% margin. Key corporate milestones include the closure of the IHH Open Offer and the strategic acquisition of the 'Fortis' and 'SRL' brands.
Key Highlights
Planned addition of 3,200+ beds by FY30, targeting a total capacity of 8,061 beds representing a 10.7% CAGR.
H1FY26 consolidated operating EBITDA margin improved to 23.3%, up from 18.4% in FY25.
Hospital business ARPOB increased to INR 24.9 Mn in H1FY26, with overall occupancy steady at 70%.
Diagnostics business (Agilus) reported H1FY26 revenue of INR 7,684 Mn with a robust 24.6% EBITDA margin.
Maintain a strong balance sheet with Net Debt to Equity at 0.23x and Net Debt to TTM EBITDA at 1.15x as of Sep 2025.
👀 What to Watch
Investors should look favorably on the clear 5-year expansion roadmap and the significant margin expansion achieved in H1FY26. The resolution of the IHH Open Offer and brand ownership issues removes major overhangs on the stock.
CRISIL Reaffirms Fortis Healthcare Ratings at AA+/Stable; Revenue Projected to Cross ₹10,000 Cr
CRISIL has reaffirmed Fortis Healthcare's long-term rating at 'AA+/Stable' and short-term rating at 'A1+', reflecting a strong business risk profile and improved operating efficiency. The company reported a 17% YoY revenue growth in H1 FY26 to ₹4,498 crore, with consolidated EBITDA margins expanding by 300 bps to 23.3%. Fortis is executing an aggressive expansion strategy, planning to add 1,200-1,500 beds by FY28, primarily through brownfield projects. Despite recent acquisitions like TMI Healthcare for ₹430 crore, the financial risk profile remains healthy with net debt/EBITDA projected to stay below 1.5x.
Key Highlights
CRISIL reaffirmed Long-Term rating at 'AA+/Stable' and Short-Term rating at 'A1+' for bank facilities and NCDs.
H1 FY26 consolidated revenue grew 17% YoY to ₹4,498 crore with EBITDA margins improving to 23.3%.
Planned addition of 1,200-1,500 beds between FY26 and FY28 to drive 10-12% revenue growth.
Gross debt expected to reach ₹3,400-3,500 crore by FY26-end following the TMI Healthcare acquisition.
Capital structure remains robust with gearing expected to stay below 0.6x in fiscal 2026.
👀 What to Watch
Investors should take confidence in the rating reaffirmation which validates the company's strong cash flow and manageable debt levels despite aggressive expansion. Monitor the progress of brownfield bed additions and any final rulings on pending legacy litigations.
CRISIL Reaffirms Fortis Healthcare’s 'AA+/Stable' Rating; Revenue Set to Cross ₹10,000 Cr
CRISIL has reaffirmed Fortis Healthcare’s long-term rating at 'AA+/Stable', following a previous upgrade in September 2025. The company reported a strong H1 FY26 with revenue growing 17% YoY to ₹4,498 crore and EBITDA margins expanding to 23.3%. Fortis is executing an aggressive expansion plan to add 1,200-1,500 beds by FY28, supported by recent acquisitions like Shrimann Superspecialty and TMI Healthcare. Despite rising debt levels to approximately ₹3,400-3,500 crore for these acquisitions, the financial risk profile remains robust with gearing expected to stay below 0.6x.
Key Highlights
CRISIL reaffirmed 'AA+/Stable' rating for ₹1,550 crore NCDs and ₹425.98 crore bank facilities.
H1 FY26 consolidated revenue rose 17% YoY to ₹4,498 crore with EBITDA margins improving 300 bps to 23.3%.
Company plans to add 1,200-1,500 beds between FY26-FY28, primarily through brownfield expansions.
Net debt/EBITDA projected to remain healthy below 1.5x in FY26 despite ₹890 crore+ in recent acquisition commitments.
Medium-term operating margins are expected to sustain in the 22-25% range driven by better operating leverage.
👀 What to Watch
Investors should take confidence in the rating reaffirmation which validates the company's improved operating efficiency and disciplined growth strategy. The stock remains a strong healthcare play as the company scales its bed capacity while maintaining a healthy balance sheet.
Fortis Healthcare Appoints New Director and Wins Delhi High Court Civil Suit
Fortis Healthcare has initiated a postal ballot to seek shareholder approval for the appointment of Mr. Mohd Shahazwan Bin Mohd Harris as a Non-Independent & Non-Executive Director. Simultaneously, the company announced a favorable ruling from the Delhi High Court in a civil suit against a third party, securing a permanent injunction. The e-voting period for the director's appointment is scheduled from December 24, 2025, to January 22, 2026. These developments reflect both a strengthening of board governance and a successful resolution of legal challenges.
Key Highlights
Appointment of Mr. Mohd Shahazwan Bin Mohd Harris as a Non-Independent & Non-Executive Director effective December 19, 2025.
Favorable Delhi High Court order dated December 19, 2025, granting a permanent injunction in a civil suit against a third party.
Postal ballot e-voting period set for 30 days, ending on January 22, 2026, at 5:00 p.m. IST.
Record date for shareholder voting eligibility was established as December 19, 2025.
👀 What to Watch
Investors should view the legal victory as a reduction in litigation risk and are encouraged to participate in the e-voting process for the board appointment. Monitor the company for further updates on board composition and strategic direction.
Fortis to Invest INR 840 Cr for Acquisition and Expansion of Bengaluru Hospital
Fortis Healthcare is acquiring the 125-bed People Tree Hospital in Bengaluru for INR 430 Crores, including debt and land. The company plans an additional investment of INR 410 Crores over the next three years to expand the facility to over 300 beds. This acquisition is part of a cluster-focused strategy to increase Fortis's Bengaluru capacity from 900 to over 1,500 beds across seven facilities. The target hospital currently generates approximately INR 74 Crores in annual revenue as of FY25.
Key Highlights
Acquisition of 100% stake in TMI Healthcare (People Tree Hospital) for a total value of INR 430 Crores.
Planned additional investment of INR 410 Crores to scale capacity from 125 to 300+ beds.
Strategic expansion in the Bengaluru cluster, targeting a total of 1,500+ beds across 7 facilities.
Target hospital currently generates ~INR 74 Crores in revenue with significant scope for operational scaling.
Transaction expected to be consummated by the end of January 2026.
👀 What to Watch
Investors should view this as a strong growth move that consolidates Fortis's position in the high-demand Bengaluru market. Monitor the execution of the 300-bed expansion and the resulting impact on consolidated margins.
Fortis Healthcare to Acquire TMI Healthcare (People Tree Hospital) for INR 430 Crores
Fortis Healthcare's subsidiary, International Hospital Limited, has signed definitive agreements to acquire 100% of TMI Healthcare Private Limited for a total consideration of INR 430 Crores. The acquisition primarily includes the People Tree Hospital in Yeshwanthpur, Bengaluru, along with the underlying land, building, and an adjacent land parcel. The specific hospital unit being acquired reported a revenue of approximately INR 73.95 Crores in FY25. This move is part of Fortis's cluster-focused growth strategy to strengthen its market position in Bengaluru.
Key Highlights
Total deal consideration of INR 430 Crores for 100% equity stake and real estate assets.
Acquisition includes People Tree Hospital, Yeshwanthpur, which generated ~INR 73.95 Crores in FY25 revenue.
The transaction involves the purchase of the hospital building and adjacent land for future scaling.
Expected completion of the acquisition is by the end of January 2026.
TMI Healthcare's consolidated revenue for FY25 stood at INR 102 Crores.
👀 What to Watch
Investors should look favorably on this acquisition as it bolsters Fortis's presence in the lucrative Bengaluru market and includes valuable land assets. Monitor the integration process and the impact on the company's overall EBITDA margins in the coming quarters.
Fortis Healthcare Amends ₹1,550 Cr NCD Terms; Reduces Interest Spread to 150 Bps
Fortis Healthcare has executed an amendment to its Debenture Trust Deed for ₹1,550 crore worth of Non-Convertible Debentures (NCDs). The company successfully negotiated a reduction in the interest spread from 192 bps to 150 bps and a 5 bps cut in arranger fees. Significantly, the NCDs will transition from secured to unsecured status, releasing the existing pledge on Agilus Diagnostics shares. Furthermore, the company has gained flexibility to dilute its stake in Agilus Diagnostics down to 51% without prior investor approval, clearing a path for a potential IPO.
Key Highlights
Interest spread reduced from 192 bps to 150 bps starting from the First Interest Reset Date
Debt status changed from Secured (1.33x pledge on Agilus shares) to Unsecured
Arranger and Structuring Bank fees reduced by 5 bps across HSBC, Mizuho, and DBS Bank
New flexibility to dilute Agilus Diagnostics stake up to 51% without prior investor approval
Negative lien established on 25,217,126 equity shares of Agilus Diagnostics Limited
👀 What to Watch
The reduction in interest costs and transition to unsecured debt indicate a strengthening credit profile and improved bargaining power. Investors should view the Agilus stake dilution flexibility as a positive step toward unlocking value through a potential subsidiary IPO.
